Stocks of Iovance Biotherapeutics Inc (NASDAQ:IOVA) traded higher last session on Wall Street, up 10.24% to $1.83.
IOVA stock price is now -42.15% away from the 50-day moving average and -74.31% away from the 200-day moving average. The market capitalization of the company currently stands at $611.10M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $2, UBS recently Downgraded its rating from Buy to Neutral for Iovance Biotherapeutics Inc (NASDAQ: IOVA). , while ‘Citizens JMP’ rates the stock as ‘Mkt Perform’
In other news, Vogt Frederick G, Interim CEO & General Counsel bought 25,000 shares of the company’s stock on May 14 ’25. The stock was bought for $42,250 at an average price of $1.69. Upon completion of the transaction, the Interim CEO & General Counsel now directly owns 374,646 shares in the company, valued at $0.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 12 ’24, Director Maynard Ryan D sold 50,000 shares of the business’s stock. A total of $503,000 was realized by selling the stock at an average price of $10.06. This leaves the insider owning 7,500 shares of the company worth $13725.0. A total of 18.66% of the company’s stock is owned by insiders.
During the past 12 months, Iovance Biotherapeutics Inc has had a low of $1.64 and a high of $12.51. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 4.18, and a quick ratio of 3.64.
The net profit margin was -176.49% and return on equity was -51.85% for IOVA. For the current quarter, analysts expect IOVA to generate $66.65M in revenue.
